Homepage

Pharming Group N.V.

PHAR NASDAQ Categories PDF
Healthcare · Biotechnology · Netherlands · Updated May 11, 1:56pm
$12.90
Price
$910.7M
Market Cap
404
Employees
0.11
Beta
Fabrice Chouraqui
CEO
Business Description

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Business History
Price Overview
Last updated: May 11, 2026 1:56pm (just now)
$12.90
-0.09 (-0.65%)
Day Range
$12.49 – $13.10
52-Week Range
$8.69 – $21.34
50-Day MA
$16.21
200-Day MA
$15.59
Volume
22,527.92
Analyst Price Targets
Low $37.00
Consensus $38.00
High $40.00
(5 analysts)
Share Structure
Outstanding 70,625,200.00
Float 73,314,887.00
Free Float 103.8%
High free float — 103.8% of shares trade freely, ~-3.8% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
API
Stock Price / EPS (Diluted)
77.63
Stock Price: $12.90
EPS (Diluted): 0.04
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
4.55
Stock Price: $12.90
Total Equity: $277.02M
Shares: 71,317,000
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
29.13
Market Cap: $910.71M
Total Debt: $98.06M
Cash: $146.02M
EBITDA: $30.62M
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$1.2B
Market Cap: $910.71M
Total Debt: $98.06M
Cash: $146.02M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
87.9%
Gross Profit: $331.56M
Revenue: $377.18M
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
5.1%
Operating Income: $19.37M
Revenue: $377.18M
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
0.8%
Net Income: $2.86M
Revenue: $377.18M
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
4.7%
Net Income: $2.86M
Total Equity: $277.02M
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
3.8%
Operating Income: $19.37M
Tax Rate: 80.3%
Equity: $277.02M
Total Debt: $98.06M
Cash: $146.02M
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
2.59
Current Assets: $299.38M
Current Liabilities: $115.79M
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.35
Short-Term Debt: $5.34M
Long-Term Debt: $92.72M
Total Debt: $98.06M
Total Equity: $277.02M
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$5.29
Revenue: $377.18M
Shares: 71,317,000
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$3.88
Total Equity: $277.02M
Shares: 71,317,000
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$0.69
Operating CF: $50.07M
CapEx: -$751,090
Shares: 71,317,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $12.90
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $2.86M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PHAR against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $198.9M $205.6M $245.3M $297.2M $377.2M
Cost of Revenue $21.1M $17.6M $25.2M $35.4M $45.6M
Gross Profit $177.7M $188.1M $220.1M $261.8M $331.6M
Operating Expenses $164.2M $169.8M $225.5M $270.4M $312.2M
Operating Income $13.6M $18.2M -$5.4M -$8.6M $19.4M
Net Income $16.0M $13.7M -$10.5M -$11.8M $2.9M
EBITDA $48.8M $33.5M $9.9M $16.3M $30.6M
EPS $0.20 $0.17 $-0.14 $-0.17 $0.04
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $191.9M $207.3M $61.7M $54.9M $146.0M
Total Current Assets $249.4M $277.5M $316.3M $278.4M $299.4M
Total Assets $397.3M $425.8M $462.9M $400.0M $499.8M
Current Liabilities $46.8M $59.7M $78.0M $73.8M $115.8M
Long-Term Debt $139.0M $131.6M $136.6M $78.2M $92.7M
Total Liabilities $204.4M $221.2M $244.1M $178.9M $222.8M
Total Equity $192.9M $204.6M $218.8M $221.1M $277.0M
Retained Earnings -$273.2M -$256.4M -$265.3M -$275.5M -$272.9M
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $37.8M $22.5M -$17.3M -$1.8M $50.1M
Capital Expenditure -$16.7M -$2.0M -$1.5M $-796,000 $-751,090
Free Cash Flow $21.1M $20.5M -$18.8M -$2.6M $49.3M
Acquisitions (net) $0 $7.3M $0 $0 -$65.5M
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks $0 $0 $0 $0 $0
Net Change in Cash -$13.2M $15.4M -$145.6M -$6.8M $91.1M
Analyst Estimates (Annual)
Metric 2027 2028 2029 2030
Revenue $395.0M
$378.5M – $411.5M
 $387.3M
$370.1M – $415.4M
 $455.4M
$435.1M – $488.5M
 $700.8M
$669.6M – $751.7M
EBITDA $46.2M
$44.3M – $48.1M
 $45.3M
$43.3M – $48.6M
 $53.3M
$50.9M – $57.1M
 $82.0M
$78.3M – $87.9M
Net Income $13.9M
$6.2M – $21.4M
 $25.9M
$24.4M – $28.4M
 $31.4M
$29.6M – $34.3M
 $51.7M
$48.7M – $56.6M
EPS — — — —
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth +3.4% +19.3% +21.1% +26.9%
Gross Profit Growth +5.8% +17.0% +18.9% +26.6%
Operating Income Growth +34.5% -129.5% -60.0% +324.7%
Net Income Growth -14.5% -177.1% -12.3% +124.1%
EBITDA Growth -31.3% -70.5% +65.2% +87.6%
Insider Trading (Recent)
Date Insider Type Shares Price Value
2004-05-27 CAMDEN PARTNERS STRATEGIC FUND II A LP A-Award 5,000.00 $0.68 $3,400
Community AI Feedback
Sign in to Contribute
No community reviews yet for PHAR. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27